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Abstract 
Background 
Influences of the Big Five personality traits on the treatment response and longitudinal course 
of depression in patients with acute coronary syndrome: A randomised controlled trial.  
Methods 
This naturalistic observational study initially recruited 1,152 ACS patients; 685 patients 
completed personality assessments at baseline, of whom 630 were followed-up one year later. 
Of the 294 patients with depression, 207 participated in a 24-week double blind trial of 
escitalopram or placebo. The remaining 87 patients who received medical treatment only and 
the 391 who had not depression were also followed in a one year naturalistic observational 
study. The Big five personality traits were assessed using the Big Five Inventory. The 
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influences of personality on the Hamilton Depression Rating Scale score changes were 
analysed using a mixed-model repeated-measures analysis of covariance. 
Results 
A Cluster analysis identified two personality types: resilient and vulnerable. The vulnerable 
personality type was characterised by lower extraversion, agreeableness, and 
conscientiousness – but higher neuroticism – than the resilient type. This personality type was 
independently associated with a poorer outcome of depression in ACS patients during the 24-
week treatment period and the one year longitudinal follow-up period compared to the 
resilient personality type, irrespective of treatment allocation.  
Limitations 
Recruitment from a single institution may limit generalisability. Personality traits were 
investigated 12-weeks after ACS; thus, the responses may have been influenced by the prior 
receipt of escitalopram. 
Conclusions 
Personality types influences the treatment outcome and longitudinal course of depression in 
ACS patients independent of antidepressant treatment.  
 
Introduction 
Depression is common in patients with acute coronary syndrome (ACS) (Rudisch and 
Numeroff, 2003). However, while the stress associated with this physical illnesses is likely to 
be an important factor, there are also likely to be variations in an individual's response to 
illness which may modify this outcome. Personality traits are key factors that can influence 
individual perceptions regarding illness-related stressors (Groves and Muskin, 2011). Several 
studies have attempted to define vulnerabilities to psychological or physical health 
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consequences following ACS, particularly the traditional type A behavior and D personality 
(Roseman et al., 1976; Denellot et al., 1995). Type A behavior is characterized by hostility, 
time urgency and competitiveness behavior patterns, and is a risk factor for cardiovascular 
disease (Roseman et al., 1976). However, most researches on type A behavior has focused on 
cardiovascular morbidity and mortality (Steptoe and Molloy, 2007) rather than depression in 
patients with heart disease. The type D personality is characterised by negative affectivity and 
social inhibition and is a risk factor for the development and persistence of depressive 
symptoms in cardiac patients (Denellot et al., 1995, Pedersen et al., 2006; Martens et al., 
2008). However, there has been still debate on the potential overlap between negative 
affectivity and depression, and whether type D is a stable personality type or a response to an 
illness (Steptoe and Molloy, 2007; Marchesi et al., 2014). Furthermore, these personality 
types (A or D) represent limited and specific aspects of personality. 
In contemporary psychology, the Five Factor Model (FFM) is the most accepted, widely 
used and comprehensive model of human personality (McCrae, 2001). The FFM consists of 
the following Big Five personality dimensions: extraversion, agreeableness, 
conscientiousness, neuroticism, and openness. Numerous studies have investigated the 
influences of FFM personality on the risk, treatment response and prognosis of depression in 
general populations (Kotov et al., 2010; Wardenaar et al., 2014; Bagby et al., 2008; 
Thibodeau et al., 2015). The FFM has also been used widely in depression in patients with 
chronic physical illness, mainly for risk investigation but also in a few studies of treatment 
response and longitudinal course (Aben et al., 2002; Westlake et al., 2005; de Jonge et al., 
2006). Other than findings showing that neuroticism is associated with the risk of depression 
in patients with cardiac disease (Westlake et al., 2005; de Jonge et al., 2006; Duits et al., 
1999), randomised trials investigating the influence of FFM personality traits on the risk of 
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depression and the course or treatment response in patients with ACS have yet to be 
conducted. 
The FFM can be investigated either as five dimensions separately (a dimensional or 
variable-centered approach) or in combination (a typological or person-centered approach) 
(Costa et al., 2002; Asendorpf, 2002). From a clinical perspective, the typological approach 
provides a more integrative framework for personality and health assessment, and thus has 
drawn more attention recently (Asendorpf, 2002). The FFM typological approach has 
revealed that overcontrolled or vulnerable personality types are associated with an increased 
risk of, or poorer treatment outcomes for depression (Wardenaar et al., 2014; Asendorpf, 2002; 
Chapman and Goldberg, 2011). However, to the best of our knowledge, no studies have used 
the FFM typological approach to investigate depression in patients with ACS.  
The aim of the study was to identify the influence of the Big Five personality traits on 
the treatment response and longitudinal course of depression in patients with ACS. The 
findings obtained using the typological approach are detailed in the main body of this 
manuscript due to their potential clinical utility, while the data obtained using the dimensional 
approach are described in the Supplementary materials. 
 
Methods 
Study overview and participants 
This analysis was conducted using data from a large naturalistic study of patients with ACS, 
the Korean DEPression in ACS (K-DEPACS) study, which also included a nested randomised 
controlled trial for depressive patients with ACS, the Escitalopram for DEPression in ACS 
(EsDEPACS) study. Comprehensive study details and eligibility criteria for the K-DEPACS 
and EsDEPACS participants have been published (Kim et al., 2014). 
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The K-DEPACS study was carried out from 2006 to investigate the epidemiology of 
depression in ACS using a naturalistic prospective design. The participants were 
consecutively recruited from among patients recently hospitalised for ACS (n = 4,809) in the 
Department of Cardiology of Chonnam National University Hospital, Gwangju, South Korea. 
All patients were treated by the study cardiologists based on international guidelines for the 
management of ACS. Those who met the eligibility criteria and agreed to participate (n = 
1,152) were assessed for depressive disorders. Following the ACS diagnosis, diagnoses of 
depressive disorders were determined using the Mini International Neuropsychiatric 
Interview (MINI) based on the criteria of the Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition (DSM-IV). The MINI is a structured diagnostic psychiatric interview 
for the DSM-IV that can be used to diagnose major or minor depressive disorder (Sheehan et 
al., 1998). Using these criteria, patients were diagnosed with a major depressive disorder 
(MDD) if they had at least one core symptom of depression (e.g. depressed mood or loss of 
interest) along with at least four other symptoms. A diagnosis of a minor depressive disorder 
was made if a patient had at least one core symptom plus at least two, but less than four, of 
the other symptoms. In our study, the criterion for duration of symptoms was within rather 
than at least 2 weeks due to the particular study design at baseline. Of those, 446 were 
diagnosed with either major or minor depressive disorder; 300 of these patients agreed to be 
randomised to a 24-week, double-blind, placebo-controlled trial investigating the efficacy and 
safety of escitalopram; i.e. the EsDEPACS study. (ClinicalTrial.gov registry number: 
NCT00419471). The primary results of the EsDEPACS trial have been published, and 
showed that escitalopram was superior to placebo (Kim et al., 2015).  
Personality was assessed 12-weeks after the baseline evaluation, then 685 (59.5%) 
received personality assessments and formed the sample for the analyses presented here. Of 
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the remaining 467 patients, 287 were lost to follow-up, 10 died, 120 refused to participate, 
and 50 were too unwell to participate on 12-weeks. Of the analysed group, 294 participants 
were diagnosed with either a major or minor depressive disorder and, of these patients, 207 
agreed to participate in the EsDEPACS study. The remaining 87 patients who had depression 
but declined participation in the trial received conventional medical treatment for ACS only 
(MTO). All patients who participated in the K-DEPACS and EsDEPACS studies were 
contacted for follow-up investigation at one year after the baseline evaluation. Written 
informed consent was collected for the K-DEPACS and EsDEPACS studies, both of which 
were approved by the Chonnam National University Hospital Institutional Review Board. 
 
Personality assessments 
Personality was assessed by the Big Five Inventory (BFI), which was selected to represent 
the core traits in FFM personality (John and Srivastata, 1999). Terminology applied to these 
five traits has been described as follows: ‘Extraversion’ - talkative, assertive, and energetic; 
‘Agreeableness’ - good-natured, cooperative, altruistic and empathic; ‘Conscientiousness’ - 
orderly, responsible, and dependable; ‘Neuroticism’ - neurotic, easily upset and not self 
confident; and ‘Openness’ - openness to experience, intellectual, imaginative, and 
independent-minded. Self-report ratings are made on a scale from 1 to 5 for each of 44 scale 
items, and higher scores represent higher levels of each given trait (John and Srivastata, 
1999). The BFI has been translated and validated in Korean (Kim et al., 2010). Unfortunately 
a prospective design with pre-morbid personality was not possible in the present clinical 
setting; however, the BFI was performed 12-weeks after the baseline assessment to minimise 
the influence of the ACS and the reaction of patients to this diagnosis. 
 Using the typological approach, personality cluster was identified using cluster analysis. 
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Result of identical analyses with the two-step procedure specified by Asendorpf et al. (2001), 
two personality types were identified: resilient and vulnerable. Ward's hierarchical clustering 
procedure was applied for the initial solution; then, iterative k-means clustering, using Ward's 
method to define the initial cluster centres, was performed. Each case was assigned to a 
cluster based on the Euclidean distance from the cluster means; all data was z-standardised to 
determine the Euclidean distance. The largest shifts in cluster coefficients were observed in 
the transition from the two- to one-cluster solution; therefore, a two-cluster solution was 
accepted as the best initial solution. The cluster centres derived from the initial solution were 
used to implement non-hierarchical k-means clustering.  
To evaluate the replicability of the final solutions, the method of Asendorpf et al. (2001) 
was used. Briefly, all cases were randomly split into halves and the full two-step procedure 
was applied to each half. Next, the participants from each half were assigned to new clusters 
according to the cluster centres of the other half of the sample. These new clusters were then 
compared to determine if they agreed with the original clusters according to Cohen's k. A 
kappa value > 0.60 was required as evidence of replication; the present results satisfied this 
criterion (replicability coefficients with Cohen's k: 0.833).   
Compared with the second cluster, the first cluster was characterized by significantly 
higher extraversion, higher agreeableness, higher conscientiousness, but lower neuroticism 
(all p < 0.001). As defined and labeled in previous studies, the first cluster was labeled as 
resilient type and the second was vulnerable type (Wardenaar et al., 2014, De Fruyt, 2002). 
The personality profiles of the two clusters are shown in Fig. 1, with z scores used for ease of 
interpretation. 
 
Outcomes 
8 
 
The primary efficacy outcome measure was change in score on the 17-item Hamilton 
Depression Rating Scale (HDRS) (Hamilton, 1960) from baseline to endpoint. The HDRS 
was administered at baseline and 24-weeks for the EsDEPACS study, and at baseline and one 
year for the K-DEPACS study.  
 
Demographic and clinical characteristics at baseline 
Baseline characteristics evaluated included demographic and depression-related 
characteristics, cardiac risk factors, and current cardiac status. Demographic characteristics 
comprised age, gender, and duration of education. Baseline HDRS score and previous history 
of depression were evaluated for depression-related characteristics. Cardiac risk factors 
assessed comprised the following: self-reported diagnoses of hypertension or diabetes 
mellitus, hypercholesterolemia (fasting serum total cholesterol level >200mg/dl), obesity 
based on body mass index (BMI), self-reported current smoking status, previous history of 
ACS, and family history of ACS. In relation to cardiac status, diagnoses of myocardial 
infarction or unstable angina were distinguished, the severity of ACS was measured by the 
Killip classification (Killip and Kimball, 1967), left ventricular ejection fraction (LVEF) was 
estimated using echocardiography, and serum cardiac biomarkers troponin I and creatinine 
kinase-MB were measured.  
 
Statistical analysis 
Baseline characteristics were compared between the two personality types (resilient vs. 
vulnerable) by χ2 or independent t tests. To identify the influence of the personality types on 
escitalopram treatment response in the EsDEPACS trial, the participants were divided into 
two groups, escitalopram vs. placebo, and mixed model repeated-measures analyses of 
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covariance (RMANCOVA) were used to assess interactions between time × group, time × 
personality type, and time × group × personality type. These variables were assessed in 
relation to the change in HDRS score at 24-weeks after adjusting for all covariates, including 
baseline HDRS score, previous depression, and previous history of ACS; a full model was 
used to avoid the risk of overfitting due to univariate pre-selection.  
The influence of the personality types on the longitudinal course of depression was 
analysed, in the K-DEPACS participants who completed the one year follow-up assessment, 
after categorising the participants into four groups: no depression, depression on MTO, 
depression on escitalopram, and depression on placebo. Mixed model RMANCOVA was then 
performed to determine the associations of time × group, time × personality type, and time × 
group × personality type on one year HDRS score changes, after adjusting for all covariates. 
Additional subgroup analyses stratified by type of depression (major vs. minor) were 
conducted to identify the influences of personality type on treatment response at 24-weeks 
and one year. Additional analyses of dimensional FFM output were conducted; these are 
described in the Supplementary material. Statistical significance was set at p < 0.05 (two-
sided), and all analyses were carried out using SPSS software version 18.0 (SPSS Inc., 
Chicago, I\L, USA). 
Results 
Recruitment 
The flow chart of recruitment is shown in Supplementary Fig. 1. Of the K-DEPACS baseline 
sample (n = 1,152), 685 (59%) patients underwent the personality assessment at 12-weeks. 
Compared with the remainder of the sample, those assessed differed significantly in the 
following respects: younger age (p = 0.012), higher baseline HDRS score (p < 0.001), past 
history of depression (p = .024), hypercholesterolemia (p = 0.004), and lower Killip class (p = 
10 
 
0.01). Of these, 207 participated in the EsDEPACS trial (104 randomised to escitalopram and 
103 to placebo); all were followed successfully for 24-weeks. There were no significant 
differences in any baseline characteristic including BFI scores between the two treatment 
groups. Of the 685 participants at baseline, 630 (92%) were followed at one year (369 with 
no depression, 84 on MTO, 87 on escitalopram, 90 on placebo). Of remaining 55 patients, 39 
were lost to follow-up, 1 died, 11 refused to participate, and 4 were too unwell to participate. 
Attrition was significantly associated with the following baseline characteristics: older age (p 
= 0.047), higher baseline HDRS score (p = 0.027), lower troponin I (p = 0.008), and less 
hypercholesterolemia (p = 0.009). 
 
Two personality types and baseline characteristics 
Of the 685 patients, 406 (59.3%) were classified as resilient and 279 (40.7%) were classified 
as vulnerable. A comparison of the baseline characteristics of the two groups is presented in 
Table 1. The vulnerable group had a higher incidence of previous depression and history of 
ACS, as well as higher baseline HDRS scores, but there were no other significant differences 
between the two groups, aside from BFI score. There were significantly more patients with 
the resilient type in the no depression group than in the depression group (69.5% vs. 30.5%, p 
< 0.001), but there were no significant differences between the randomised groups of the 
EsDEPACS trial. 
 
Treatment response at 24-weeks 
HDRS score changes during the 24-week EsDEPACS trial were compared between the 
escitalopram vs. placebo groups and resilient vs. vulnerable personality types using mixed 
model RMANCOVA adjusted for all other baseline characteristics except BFI score, and are 
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summarised in Table 2 and Fig. 2. The HDRS score decreased significantly more in the 
escitalopram treatment group compared to placebo (F = 7.68, p = 0.006) and, independent of 
treatment group, more in patients with the resilient personality type compared with the 
vulnerable type (F = 12.05, p < 0.001). There was no significant interaction between 
personality type and treatment group. 
 
Outcome at one year 
The HDRS score changes at the one year follow-up were analysed similarly, as summarised 
in Table 3 and Fig. 3. The resilient personality type was associated independently and with a 
significantly greater decrease in HDRS score compared with the vulnerable type at one year 
(F = 34.18, p = 0.001). There was no significant interaction between personality type and the 
depression/treatment group. 
 
Subgroup analysis according to depression diagnosis 
Of the 207 patients who participated in the EsDEPACS trial, 92 (44.4%) were diagnosed with 
minor depression and 115 (55.6%) were diagnosed with major depression at baseline. Of the 
630 patients who were followed-up after one year in the K-DEPACS trial, 119 (18.9%) were 
diagnosed with minor depression and 50 (7.9%) were diagnosed with major depression at 
baseline. The changes in HDRS scores at the 24-week and one year follow-ups in each 
subgroup were analysed similarly to the main analysis. In the minor depression subgroup, 
there was a significantly greater decrease in the HDRS scores of resilient-type versus 
vulnerable-type patients at 24-weeks (F = 9.61, p = 0.003) but no significant difference 
between treatment groups (F = 1.18, p = 0.24). In the major depression subgroup, there was a 
significantly greater decrease in the HDRS score of the escitalopram group compared to the 
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placebo group (F = 4.70, p = 0.033) but no significant difference between the two personality 
types (F = 2.00, p = 0.16). At one year, neither personality type nor treatment group had a 
significant influence on treatment response, nor was there a significant interaction between 
personality type and treatment group in either subgroup analysis at 24-weeks or one year. 
 
Dimensional approaches 
Results from the five dimensional scores are described in the Supplementary material and  
Supplementary table 1; these findings were similar to those obtained using the typological 
approach.. In the 24-week treatment response analyses, escitalopram and three personality 
dimensions (agreeableness, conscientiousness, and neuroticism) were independently 
associated with HDRS score at the trial end-point, but there were no significant interactions 
between personality dimensions and randomization group (all p > 0.20). Higher 
agreeableness and conscientiousness were associated with lower HDRS score, while higher 
neuroticism was associated with higher HDRS score at the trial end-point. 
Similarly, in the one year outcome analyses, all personality dimensions apart from 
openness were independently associated with the HDRS score at the trial end-point, and there 
were no significant interactions between personality dimensions and the depression/treatment 
group (all p > 0.10). Higher extraversion, agreeableness, and conscientiousness were 
associated with lower HDRS score, while higher neuroticism was associated with higher 
HDRS score at the trial end-point. 
Discussion 
The principal findings of the investigation were that a vulnerable personality group could be 
identified from cluster analysis of FFM output which was independently associated with 
worse outcome of depression following ACS, both within a 24-week randomised controlled 
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trial and over a one year observational period, and independent of depression treatment 
allocation. Comparable findings were also observed for dimensional approaches of 
personality traits from the FFM. To the best of our knowledge, the present study is the first to 
use the full FFM personality inventory to investigate the treatment response and/or 
longitudinal course of depression in patients not only with ACS but also with any physical 
illnesses. 
In personality research, dimensional approaches are quantitatively more informative than 
typological approaches, but translate poorly to individual patients (Costa et al., 2002), while 
typological approaches may be more useful in clinical settings. However, the replicability and 
utility of the FFM personality prototypes are still debated (Costa et al., 2002). In previous 
studies, two (Wardenaar et al., 2014, De Fruyt, 2002) or three clusters (Chapman and 
Goldberg, 2011, Berry et al., 2007) were replicated in various samples. In agreement with 
previous reports, we identified two personality clusters (resilient vs. vulnerable) in our sample. 
A two-cluster solution usually bifurcates the sample into groups which might be characterized 
as socially desirable vs. less desirable which, although coarse, has been suggested as useful in 
screening (De Fruyt, 2002). Other than the FFM personality types, the similarly bifurcated 
type D personality has received attention regarding the incidence and persistence of 
depression in cardiac patients (Denollet et al., 1995; Pedersen et al., 2006; Martens et al., 
2008). However, the FFM typology offers a potentially more comprehensive approach. The 
vulnerable personality type in our study might well include the type D personality, as the 
concepts of 'negative affectivity’ and ‘social inhibition' in type D personality are consistent 
with the high neuroticism and low agreeableness in the vulnerable type from FFM (Denollet 
et al., 2005). Our results would help to integrate various opinions of previous personality 
researches in patient with ACS. 
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Although placebo-controlled trials have investigated the influence of FFM personality 
features on the treatment response to antidepressants, the results are controversial. A recent 
randomised controlled trial of patients with MDD found that personality predicted treatment 
outcome regardless of treatment type (Bagby et al., 2008; Thibodeau et al., 2015), but there 
was also a significant interaction in which personality predicted a differential response to 
treatment type (Bagby et al., 2008). Others have suggested that there is an interaction 
between the treatment outcome of paroxetine and neuroticism in MDD patients (Tang et al., 
2009). 
Differences in sample characteristics might be responsible for the discrepancy. Whereas 
approximately 60% of the participants were female in the previous study, more than 60% of 
the participants in the EsDEPACS study were male, which reflects the prevalence of ACS 
(Bagby et al., 2008; Thibodeau et al., 2015, Tang et al., 2009). These differences are 
important because the relationships between FFM personality and depression differ by gender 
(Fanous et al., 2007; Kendler and Gardner 2014). The vulnerable type may be associated with 
poor outcome because the FFM model of personality shares generic risk factors with 
depression (Kendler and Myers, 2010), which has a greater genetic overlap in men than 
women (Fanous et al., 2007). Next, it is possible that the participants of our study had some 
intensified personality characteristics compared to general populations, given longstanding 
suggestions of associations between personality traits and risk of coronary heart disease 
(Rosenman  et al., 1976; Sirri et al., 2012). For example, type A behavior is more prevalent 
in patients with cardiovascular disease compared with other medical disorders (Sirri et al., 
2012). Finally, the timing of the personality assessment could give rise to different results. In 
our study, personality traits were investigated 12-weeks after ACS and it is possible that 
responses might have been influenced by prior receipt of escitalopram. However, research on 
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the influences of selective serotonin reuptake inhibitors has yielded both positive (Tang et al., 
2009; Du et al., 2002) and negative findings (Knorr et al., 2012; Jylhä et al., 2012). In our 
data, there were no significant differences between the escitalopram and placebo groups for 
either personality type. 
Although there have been consistent reports of FFM personality influences on 
longitudinal course of depression in general populations from both typological or 
dimensional approaches of FFM (Wardenaar et al., 2014; Wiersma et al., 2011; Quilty et al., 
2008), there has been no research investigating influences of the full five dimensions of FFM 
personality on longitudinal course in co-morbid depression with ACS. One published article 
investigated two selected dimensions of FFM, neuroticism and extraversion, and reported that 
pre-morbid neuroticism was a risk factor for depression (incidence and persistence) after 
somatic illness events, including myocardial infarction (de Jonge et al., 2006). Considering 
the FFM typological approach, there has been one published observational study of predictive 
value for treatment efficacy in MDD in primary care (Wardenaar et al., 2014). This classified 
MDD patients to vulnerable vs. resilient classes, and recovery was found to be slower in the 
vulnerable class. The results are in line with ours which vulnerable personality predict poor 
outcome. However, the previous study also reported a significant three-way interaction 
between personality class, time, and treatment allocation (Wardenaar et al., 2014), whereas 
we did not find an interaction between personality class and treatment allocation. There are 
important methodological differences between two studies. First, gender disparities may be 
important, as previously discussed, as about 70% of participants of the previous study were 
female (Wardenaar et al., 2014). Second, the previous study compared treatment groups 
receiving both pharmacotherapy and psychotherapy, whereas our comparison groups did not 
include psychotherapy. The role of personality might be treatment-specific; for example, 
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depressed patients with higher neuroticism were found to be more likely to respond to 
pharmacotherapy than psychotherapy (Bagby et al., 2008).  
From a psychological perspective, characteristics of the resilient type could explain our 
results. Resilient personality type has been previously associated with a high level of ego-
resiliency and a moderate standing on ego-control (Asendorpf et al., 1999). Ego-resiliency 
describes capacity to respond flexibility to changing situational demands, particularly 
stressful situations; ego-control refers to the capacity to constrain motivation and emotional 
impulses (Block et al., 1980). At the time of ACS diagnosis and treatment, resilient 
individuals may therefore more easily adapt to the stressful situation. 
The subgroup analyses of the EsDEPACS trial revealed that only personality type 
significantly influenced treatment response in the minor depression subgroup, while only 
treatment type (escitalopram or placebo) significantly influenced treatment response in the 
major depression subgroup. The negative result of treatment type in the minor depression 
group was identical to the primary results of the EsDEPACS trial (Kim et al., 2015). These 
subgroup analyses also indicated that the influence of personality type was more significant 
in those with minor depression than in those with major depression. However, due to the 
small sample sizes in the subgroup analyses, and the negative results at the one year follow 
up, further studies are required to confirm these findings. 
The present findings have some potential clinical implications. First, personality and 
escitalopram were independently and non-interactively associated with change in depressive 
symptoms over a 24-week period in depressed patients with ACS. In other words, 
escitalopram was effective in the treatment of depressive symptoms following ACS 
regardless of personality. Second, personality independently predicted the longitudinal course 
of depressive symptoms in patients with ACS. In particular, the vulnerable group – a cluster 
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characterized by higher neuroticism, lower extraversion, lower agreeableness, and lower 
conscientiousness – had worse long-term outcomes. The vulnerable personality group could 
be a target for potential interventions for reducing depressive symptoms, although the impact 
of such interventions requires further evaluation. 
Strengths of the study included its prospective observational and interventional study 
design with large sample of ACS patients. The intervention was a double-blind randomised 
placebo-controlled trial. Participants were recruited at baseline consecutively from all eligible 
patients with a recent ACS and were followed at one year thereafter, which reduced the risk 
of error arising from heterogeneous examination times. With comprehensive human 
personality model of FFM, our results would help to integrate various opinions of previous 
personality researches in patient with ACS. Also, we analysed the influences of personality 
using both typological and dimensional approaches, maximizing output and allowing cross-
testing of hypotheses. 
Several limitations should be considered when interpreting the results. First, recruitment 
at a single institution may limit the sample generalisability; however, the single-center study 
has strengths in terms of consistency in the evaluation and treatment of patients. Second, 
personality traits were investigated 12-weeks after ACS as mentioned above. Third, of the 
1,152 participants in the K-DEPACS cohort, only 685 (59%) were assessed for personality, 
and some baseline characteristics differed in analysed participants, which could have 
influenced the results. Fourth, the vulnerable group had a higher incidence of previous 
depression and ACS than the resilient group at baseline. Although these were considered as 
covariates, it should be borne in mind that the vulnerable personality was resulted in previous 
depression or ACS (scar effect) (fanous et al., 2007). However, the scar effect of previous 
depression on current personality is still debated hypothesis (fanous et al., 2007, Jylhä et al., 
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2009). Similarly, although the baseline HDRS scores were included as covariates in the 
RMANCOVA, we also couldn't exclude the effect of baseline depressive mood on personality 
characteristics (state effect) (Jylhä et al., 2009) because the baseline HDRS score was higher 
in the vulnerable group than that in the resilient group. However, in previous longitudinal 
study, the level of neuroticism and extraversion were still differ between depressive patients 
and the general population, after controlling depression and excluding scare effect. Thus, 
FFM personality features have a trait effect on depression (Jylhä et al., 2009). Finally, 
although the FFM typological approach gave clear potentially clinically relevant findings, 
replication of the prototype remains a critical objective. Although they have potential clinical 
utility for screening, dimensional approaches have been found to be consistently better 
predictors of ego resiliency and control (Costa et al., 2002). 
In conclusion, personality influences the longitudinal course of depression in ACS 
patients independent of treatment allocation. Escitalopram was effective in the treatment of 
depressive symptoms following ACS regardless of personality. Further clinical trials should 
assess treatment response to other antidepressants in depressed patients with ACS according 
to personality characteristics. 
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Fig. 1. Personality profile clusters according to Big Five Inventory z-scores (n = 685). 
 
Fig. 2. Changes in the Hamilton Depression Rating Scale (HDRS) score over 24-weeks 
according to treatment status and personality cluster (n = 207). The results were obtained 
using repeated measures analysis of covariance in a mixed model with the corresponding 
baseline HDRS scores, age, gender, education, history of depression, hypertension, diabetes, 
current smoking, obesity, hypercholesterolemia, personal and family history of acute 
coronary syndrome, diagnosis of acute coronary syndrome, Killip class, ejection fraction, and 
levels of creatinine kinase-MB and troponin I. Significant differences in time × group and 
time × personality type interactions were found on all outcomes (p = 0.006 and p < 0.001, 
respectively). 
 
Fig. 3. Changes in the Hamilton Depression Rating Scale (HDRS) score over one year 
according to depression diagnosis, treatment status, and personality cluster (n = 630). The 
results were obtained using repeated measures analysis of covariance in a mixed model with 
the corresponding baseline HDRS scores, age, gender, education, history of depression, 
hypertension, diabetes, current smoking, obesity, hypercholesterolemia, personal and family 
history of acute coronary syndrome, diagnosis of acute coronary syndrome, Killip class, 
ejection fraction, and levels of creatinine kinase-MB and troponin I. Significant differences in 
time × group and time × personality type interactions were found for all outcomes (p < 0.001, 
both). 
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Table 1. Baseline characteristics by personality cluster 
ACS, acute coronary syndrome; CK-MB, creatinin kinase-MB; HDRS, Hamilton Depression 
Rating Scale; LVEF, left ventricular ejection fraction; SD, standard deviation. 
 
 
 
 Total Personality cluster p 
  Resilient Vulnerable  
 (n = 685) (n = 406) (n = 279)  
Demographic factors     
Age, mean (SD), years 57.9 (11.0) 58.5 (10.7) 57.0 (11.4) 0.084 
Female gender, n (%), 202 (29.5) 112 (27.6) 90 (32.3) 0.19 
Education, mean (SD), years 9.9 (4.5) 9.6 (4.7) 10.2 (4.3) 0.10 
Psychological factors     
HDRS score, mean(SD) 8.23 (6.4) 6.6 (5.8) 10.7 (6.5) < 0.001 
Previous depression, n (%) 32 (4.7) 13 (3.2) 19 (6.8) 0.03 
Extraversion, mean (SD) 3.0 (0.5) 3.2 (0.5) 2.8 (0.4) < 0.001 
Agreeableness, mean (SD) 3.7 (0.5) 4.0 (0.3) 3.4 (0.44) < 0.001 
Conscientiousness, mean (SD) 3.7 (0.5) 3.9 (0.4) 3.3 (0.4) < 0.001 
Neuroticism, mean (SD) 2.7 (0.6) 2.3 (0.4) 3.2 (0.4) < 0.001 
Openness, mean (SD) 2.9 (0.6) 2.8 (0.6) 2.9 (0.5) 0.58 
Cardiac risk factors     
Hypertension, n (%) 327 (47.7) 183 (45.1) 144 (51.6) 0.09 
Diabetes mellitus, n (%) 151 (22.0) 89 (21.9) 62 (22.2) 0.93 
Hypercholesterolemia, n (%) 364 (53.1) 211 (52.0) 153 (54.8) 0.46 
Obesity, n (%) 297 (43.4) 170 (41.9) 127 (45.5) 0.34 
Current smoker, n (%) 258 (37.7) 153 (37.7) 105 (37.6) 0.99 
Previous history of ACS, n (%) 35 (5.1) 15 (3.7) 20 (7.2) 0.04 
Family history of ACS, n (%) 22(3.2) 12 (3.0) 10 (3.6) 0.65 
Current cardiac status     
ACS diagnosis, n (%)    0.58 
Myocardial infarction 494 (72.1) 296 (72.9) 198 (71.0)  
Unstable angina 191 (27.9) 110 (27.1) 81 (29.0)  
Killip class > 1, n (%) 106 (15.5) 56 (13.8) 50 (17.9) 0.14 
LVEF, mean (SD), % 60.8 (11.3) 60.4 (11.5) 61.3 (10.9) 0.30 
Troponin I, mean (SD), mg/dL 9.2 (13.8) 8.5 (13.4) 10.2 (14.3) 0.12 
CK-MB, mean (SD), mg/dL 16.7 (36.7) 16.1 (34.0) 17.6 (40.4) 0.61 
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Table 2. Effects of medication and personality in a 24-week double-blind trial on Hamilton 
Depression Rating Scale scores of patients with acute coronary syndrome (n = 207) 
 HDRS, mean (SD) 
F p
a
 Post hoc 
 At baseline 24-weeks 
Time 15.6 (4.7) 9.3 (6.0) 2.48 0.12 - 
Time x Randomization group   7.68 0.006 - 
  Depression on escitalopram 15.9 (5.0) 8.5 (6.1)    
  Depression on placebo 15.2 (4.4) 10.2 (5.8)    
Time x Personality type   12.05 < 0.001 - 
  Resilient 15.1 (4.3) 7.5 (5.5)    
  Vulnerable 15.9 (4.9) 10.6 (6.0)    
Time x Group x Personality type  < 0.01 0.97 N.S. 
 
HDRS, Hamilton Depression Rating Scale; SD, standard deviation.  
a Repeated-measures analyses of covariance, adjusted for all variables. 
 
 
 
Table 3. Effects of depression, treatment status, and personality on one year outcomes of patients with 
acute coronary syndrome (n = 630) 
 HDRS, mean (SD) 
F p
a
 Post hoc 
 At base One year 
Time 8.0 (6.3) 6.0 (5.4) 7.25 0.007 - 
Time x Group   11.39 < 0.001  
  No depression (N) 3.7 (2.6) 4.1 (4.3) 
  
M < N,E,P 
& 
E > P 
  Depression on MTO (M) 11.3 (3.6) 10.0 (5.7) 
  Depression on escitalopram (E) 15.7 (4.9) 7.1 (5.6) 
  Depression on placebo (P) 15.2 (4.4) 8.9 (5.2) 
Time x Personality type   34.18 < 0.001  
  Resilient 6.4 (5.6) 4.4 (4.2)   - 
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  Vulnerable 10.5 (6.4) 8.4 (6.0) - 
Time x Group x Personality type  .02 0.99 N.S. 
HDRS, Hamilton Depression Rating Scale; MTO, medical treatment only; SD, standard deviation 
a
Repeated-measures analyses of covariance, adjusted for all variables. 
 
 
Highlights 
 Vulnerable personality is related with poor outcome of depression in ACS. 
 Vulnerable personality characterized by low E,A,C but high N in ACS. 
 Personality influences on depression independent of antidepressant treatment. 
 Personality independently predicts the longitudinal course of depression in ACS. 
 A Single site recruitment and the time of personality assessment are limitations. 
 
Fig. 1. Personality profile clusters according to Big Five Inventory z-scores (n = 685). 
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Fig. 2. Changes in the Hamilton Depression Rating Scale (HDRS) score over 24-weeks 
according to treatment status and personality cluster (n = 207). The results were obtained 
using repeated measures analysis of covariance in a mixed model with the corresponding 
baseline HDRS scores, age, gender, education, history of depression, hypertension, diabetes, 
current smoking, obesity, hypercholesterolemia, personal and family history of acute 
coronary syndrome, diagnosis of acute coronary syndrome, Killip class, ejection fraction, and 
levels of creatinine kinase-MB and troponin I. Significant differences in time × group and 
time × personality type interactions were found on all outcomes (p = 0.006 and p < 0.001, 
respectively). 
 
 
  
 
 
 
 
 
 
  
Fig. 3. Changes in the Hamilton Depression Rating Scale (HDRS) score over one year 
according to depression diagnosis, treatment status, and personality cluster (n = 630). The 
results were obtained using repeated measures analysis of covariance in a mixed model with 
the corresponding baseline HDRS scores, age, gender, education, history of depression, 
hypertension, diabetes, current smoking, obesity, hypercholesterolemia, personal and family 
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history of acute coronary syndrome, diagnosis of acute coronary syndrome, Killip class, 
ejection fraction, and levels of creatinine kinase-MB and troponin I. Significant differences in 
time × group and time × personality type interactions were found for all outcomes (p < 0.001, 
both). 
 
 
